Home / Glypican 3 / Recombinant Human Glypican 3 Protein

Recombinant Human Glypican 3 Protein

Catalog #: 2119-GP
7 Citations Datasheet / COA / SDS

Carrier Free

Catalog # Availability Size / Price Qty
2119-GP-050/CF

With Carrier

Catalog # Availability Size / Price Qty
2119-GP-050
Best Seller
Graph showing bioactivity of human Glypican-3 protein
1 Image
Product Details
Citations (7)
FAQs
Reviews
Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human Glypican 3 Protein Summary

Product Specifications

Purity
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
Activity
Measured by its binding ability in a functional ELISA. When Recombinant Human Glypican 3 is immobilized at 0.5 μg/mL (100 µL/well), the concentration of Recombinant Human FGF basic 146 aa (Catalog # 233-FB) that produces 50% of the optimal binding response is approximately 0.6-3 ng/mL.
Source
Mouse myeloma cell line, NS0-derived human Glypican 3 protein
Gln25-His559 with a C-terminal 6-His tag
Accession #
P51654.1
N-terminal Sequence
Analysis
No results obtained: Gln25 predicted, Ser359 & Val483
Structure / Form
Glypican 3 is subject to endoproteolytic processing by proprotein convertases (PC). By amino acid sequencing, three peptides (the first with a blocked N-terminus most likely starts with Gln25, the second peptide starts with Ser359 after a furin cleavage site, and the third peptide starts with Val483) are present in the recombinant GPC3 preparation. Peptides 2 and 3 are detected at a 1:1 ratio. All three peptides remained associated via disulfide bonds.
Predicted Molecular Mass
61.6 kDa
SDS-PAGE
60-100 kDa, non-reducing conditions

Product Datasheets

You must select a language.

x

2119-GP (with carrier)

Product Datasheet
COA
SDS

You must select a language.

x

2119-GP/CF (carrier free)

Product Datasheet
COA
SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

2119-GP

Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 10 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

2119-GP/CF

Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity Graph showing bioactivity of human Glypican-3 protein View Larger

Recombinant human Glypican 3 (2119-GP) binds recombinant human FGF basic 146 in a functional ELISA. The concentration of recombinant human FGF basic 146 that produces 50% of the optimal binding response is 0.6-3 ng/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: Glypican 3

Glypicans (GPC) are a family of heparan sulfate proteoglycans that are attached to the cell surface by a glycosylphosphatidylinositol (GPI) anchor. Six members of this family have been identified in mammals (GPC1-GPC6). All glypican core proteins contain an N-terminal signal peptide, a large globular cysteine-rich domain (CRD) with 14 invariant cysteine residues, a stalk-like region containing the heparan sulfate attachment sites, and a C-terminal GPI attachment site. While glypican proteins do not share strong amino acid sequence identity (they range from 17-63%), the conserved cysteine residues in their CRDs suggests similarity in their
three‑dimensional structure (1, 2).

Mutations in GPC3 cause a rare disorder in humans, Simpson-Golabi-Behmel Syndrome, which is characterized by pre and postnatal overgrowth of multiple tissues and organs and an increased risk for developing embryonic tumors (3). These features are also present in the mouse knock-out of GPC3 indicating that GPC3 regulates cell survival and inhibits cell proliferation during development (4). Glypican 3 has been implicated in regulating many different signaling pathways including: IGF, FGF, BMP and Wnt. An endoproteolytic processing of GPC3 by proprotein convertases is required for the modulation of Wnt signaling (5). Direct interaction with FGF-basic has been observed and is mediated by the heparan sulfate chains (6).

References
  1. Filmus, J. and S.B. Selleck (2001) J. Clinical Invest. 108:497. 
  2. De Cat, B and G. David (2001) Seminars in Cell & Dev. Biol. 12:117. 
  3. Pilia, G. et al. (1996) Nat. Genet. 12: 241. 
  4. Cano-Gauci, D.F. et al. (1999) J. Cell Biol. 146: 255.
  5. De Cat, B. et al. (2003) J. Cell Biol. 163:625.
  6. Song, H.H. et al. (1997) J. Biol. Chem. 272:7574.
Entrez Gene IDs
2719 (Human); 14734 (Mouse); 25236 (Rat); 102137748 (Cynomolgus Monkey)
Alternate Names
DGSX; Glypican 3; glypican proteoglycan 3; glypican-3; GPC3; GTR2-2; heparan sulphate proteoglycan; Intestinal protein OCI-5; MXR7; OCI5; OCI-5; secreted glypican-3; SGB; SGBS; SGBS1SDYS

Citations for Recombinant Human Glypican 3 Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

7 Citations: Showing 1 - 7
Filter your results:

Filter by:

  1. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity
    Authors: TL Hickman, E Choi, KR Whiteman, S Muralidhar, T Pai, T Johnson, A Parikh, T Friedman, M Gilbert, B Shen, L Barron, KE McGinness, SA Ettenberg, GT Motz, GJ Weiss, A Jensen-Smi
    PLoS ONE, 2022-05-04;17(5):e0266980.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  2. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells
    Authors: T Ueda, A Kumagai, S Iriguchi, Y Yasui, T Miyasaka, K Nakagoshi, K Nakane, K Saito, M Takahashi, A Sasaki, S Yoshida, N Takasu, H Seno, Y Uemura, K Tamada, T Nakatsura, S Kaneko
    Cancer Sci., 2020-03-31;111(5):1478-1490.
    Species: Mouse
    Sample Types: In Vivo
    Applications: In Vivo
  3. Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery
    Authors: M Miura, N Fujinami, Y Shimizu, S Mizuno, K Saito, T Suzuki, M Konishi, S Takahashi, N Gotohda, K Suto, T Yoshida, T Nakatsura
    Oncol Lett, 2020-02-05;19(4):2657-2666.
    Species: Human
    Sample Types: Plasma
    Applications: ELISA Development
  4. Epitope mapping by a Wnt-blocking antibody: evidence of the Wnt binding domain in heparan sulfate
    Sci Rep, 2016-05-17;6(0):26245.
    Species: Human
    Sample Types: Cell Culture Supernates
    Applications: ELISA (Standard)
  5. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Clin. Cancer Res., 2012-05-10;18(13):3686-96.
    Applications: ELISA (Standard)
  6. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Authors: Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y
    Clin. Cancer Res., 2006-05-01;12(9):2689-97.
    Applications: ELISA (Standard)
  7. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10.
    Authors: Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, Komori H, Fukuma D, Baba H, Nishimura Y
    Cancer Res., 2006-02-15;66(4):2414-22.
    Species: Mouse
    Sample Types: Whole Cells
    Applications: Bioassay

FAQs

No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human Glypican 3 Protein

There are currently no reviews for this product. Be the first to review Recombinant Human Glypican 3 Protein and earn rewards!

Have you used Recombinant Human Glypican 3 Protein?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review